Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 226461/Z/22/Z | Other Grant/Funding Number | Wellcome Trust |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Makerere University | OTHER |
| Infectious Diseases Research Collaboration, Uganda | OTHER |
Not provided
Not provided
Not provided
Not provided
General objective
This pilot study aims to compare the prevalence of resistance in bacteria causing UTIs among patients seeking care outside the hospital settings (CDROs) to the WHO-GLASS data.
Specific objectives
2-1 Primary objectives:
2-2 Secondary objectives:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Namuwongo community | The Namuwongo informal settlement is located in the urban area of Kampala, Uganda. An estimated 70% of residents in the informal settlement routinely (within the last month) use antibiotics. Houses are overcrowded with residents paying to use public toilets. The investigators are recruiting from community drug retail outlets and the outpatient department of Kitsugu health centre located next to Namuwongo. | ||
| Muyenga community | The Muyenga and Bukasa neighbourhoods are also located in the urban area of Kampala, Uganda, but is more affluent than the Namuwongo informal settlement. Residents in Muyenga can afford more expensive treatments at community drug retail outlets (CDROs)/clinics. The investigators are recruiting from community drug retail outlets and the outpatient department of Naguru hospital located next to Muyenga and Bukasa neighbourhoods. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| A comparison of resistance profiles between GLASS and community uropathogens in Uganda | Prevalence of antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae isolates causing urinary tract infections, comparing GLASS surveillance data and data collected in the community in Uganda. Resistance will be measured as the proportion of isolates non-susceptible to key antibiotic classes (e.g., third-generation cephalosporins, fluoroquinolones, carbapenems). | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Patient pathway and antibiotic use in the community | Characterisation of the patient pathway from symptom onset to days 7 and 28 in individuals with urinary tract infections, and its association with antibiotic use patterns (e.g., timing, type, source, appropriateness). Collect information on healthcare seeking behaviour for eligible patients, including their sociodemographic information, antibiotics purchased, and cost of antibiotics. |
Not provided
Inclusion criteria:
acute (< 2 weeks) dysuria. increased urinary urgency and frequency, irritation, discharge. increased lower abdominal pain or discomfort and sometimes gross haematuria.
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
All patients presenting with acute UTIs arriving in CDROs/clinics and hospitals within the boundaries of the two study communities are eligible to enrol (Namuwongo informal settlement, Muyenga, and Bukasa neighbourhoods) during the 12-month study collection period.
Workers from CDROs and healthcare clinics/ hospital outpatient departments from the same two communities will be asked to complete the surveys.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Infectious Diseases Research Collaboration (IDRC), Uganda | Kampala | Central Region | PO Box 7475 | Uganda |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31703645 | Background | Gebremariam G, Legese H, Woldu Y, Araya T, Hagos K, GebreyesusWasihun A. Bacteriological profile, risk factors and antimicrobial susceptibility patterns of symptomatic urinary tract infection among students of Mekelle University, northern Ethiopia. BMC Infect Dis. 2019 Nov 8;19(1):950. doi: 10.1186/s12879-019-4610-2. | |
| 25853778 |
Not provided
Not provided
IPD would contain identifiable personal information. Therefore, the anonymised data will be collected through REDCap which is a secure data management tool.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Urine sample and perianal swab
| 28 days |
| Appropriateness of antimicrobial use in the treatment | Proportion of UTI cases in the community with microbiologically confirmed E. coli or K. pneumoniae where the prescribed or obtained antibiotic treatment was appropriate, based on standard treatment guidelines and the organism's resistance profile. | 7 days after enrolment |
| Retail outlet determinants of treating healthcare-seeking among patients with suspected UTIs | The investigators are collecting information on the number of UTIs presenting at community drug retail outlets over twelve months, antibiotic availability in the community drug retail outlet, compliance with regulations, and healthcare worker training level. | through study completion, an average of 1 year |
| Antibiotic residues and AMR in two neighbourhoods in Kampala | Detection of antibiotic residues and antimicrobial resistant organisms in environmental water samples from channels linking the two study neighbourhoods. Through detection of antibiotic residues and testing of microorganisms isolated from the waterway and soil in the surrounding areas. | through study completion, an average of 1 year |
| Comparison of the diagnostic accuracy and usability of 'Utilizer ID' to Gold Standard microbiology, culture and sensitivity | Determination of the accuracy of the UTIlizer test with a comparison of positive, negative predictive values, sensitivity and specificity of the test | through study completion, an average of 1 year |
| Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84. doi: 10.1038/nrmicro3432. Epub 2015 Apr 8. |
| 32727445 | Background | Cambaco O, Alonso Menendez Y, Kinsman J, Sigauque B, Wertheim H, Do N, Gyapong M, John-Langba J, Sevene E, Munguambe K. Community knowledge and practices regarding antibiotic use in rural Mozambique: where is the starting point for prevention of antibiotic resistance? BMC Public Health. 2020 Jul 29;20(1):1183. doi: 10.1186/s12889-020-09243-x. |
| 26980439 | Background | Mbonye AK, Buregyeya E, Rutebemberwa E, Clarke SE, Lal S, Hansen KS, Magnussen P, LaRussa P. Prescription for antibiotics at drug shops and strategies to improve quality of care and patient safety: a cross-sectional survey in the private sector in Uganda. BMJ Open. 2016 Mar 15;6(3):e010632. doi: 10.1136/bmjopen-2015-010632. |
| 33845163 | Background | Frost I, Kapoor G, Craig J, Liu D, Laxminarayan R. Status, challenges and gaps in antimicrobial resistance surveillance around the world. J Glob Antimicrob Resist. 2021 Jun;25:222-226. doi: 10.1016/j.jgar.2021.03.016. Epub 2021 Apr 15. No abstract available. |
| 30700019 | Background | Collignon PJ, McEwen SA. One Health-Its Importance in Helping to Better Control Antimicrobial Resistance. Trop Med Infect Dis. 2019 Jan 29;4(1):22. doi: 10.3390/tropicalmed4010022. |
| 31261988 | Background | Collignon P, Beggs JJ. Socioeconomic Enablers for Contagion: Factors Impelling the Antimicrobial Resistance Epidemic. Antibiotics (Basel). 2019 Jun 30;8(3):86. doi: 10.3390/antibiotics8030086. |
| 35065702 | Background | Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19. |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |